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between ANX≥8/DEP≥8 rates during/after RT vs BSL. The 
impact of ICIQ/IPSS scores, as well as that of BSL ANX/DEP, 
on the risk of ANX≥8/ DEP≥8 at 6-12 months was tested in a 
logistic regression model.  
Results: The rates of ANX≥8 did not differ from BSL at any 
time, though an increase was found at 3-6 months (6 months 
vs BSL: 23.3% vs 14.8%, p=0.12). On the contrary, DEP≥8 was 
significantly higher during and after RT (6 months vs BSL: 
22.2% vs 8.8%, p=0.02; difference at 12 months not 
statistically significant). No impact on ANX≥8/DEP≥8 of RT 
intent, fractionation, AAD or RT technique emerged at any 
time. 
ANX≥8 at 6-12 months was predicted by 2-variable models 
including BSL ANX and ICIQ scores at corresponding times or, 
alternatively, at RT end, with high discriminative power (AUC 
ranging between 0.86 and 0.90). The same variables also 
predicted DEP≥8 at 6 months (AUC=0.88). A further analysis 
showed that the changes in ANX≥8/DEP≥8 over time are 
highly modulated by ICIQ score (Figure1). 
 
Conclusions: Incontinence, during and after PoP WPRT, and 
baseline ANX/DEP are major factors in increasing the risk of 
clinically significant anxiety/depression. End RT ICIQ score is 
a good predictor of increased risk of ANX/DEP at 6-12 
months. 
   
 
Debate: Should participation to databases be made 
mandatory  
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Clinical decision is a complex moment and, as stated by Sir 
W.Osler, ‘Medicine is a science of uncertainty and an art of 
probability’. 
Medical doctors foster their ‘internal databases of 
knowledge’ by daily clinical practice, but time-by-time their 
performances question their capacity to storage and to 
communicate data, as well as to act efficiently.  
The rapid learning technology is nowadays supporting the 
transfer of this process to ‘external databases of knowledge’, 
with the aim to have less individual variability in the 
understanding of the knowledge and more reliability in the 
prediction of the outcomes.  
By rapid-learning technology data routinely generated 
through patient care and clinical research feed into an ever-
growing databank or set of coordinated databases. The 
health care system “learns” by routinely and iteratively 
collecting data in a planned and strategic manner, generating 
evidence through retrospective analysis of existing data as 
well as data from prospective studies and generating new 
hypotheses for investigation.  
Even if many issues in term of data definition, accuracy and 
interoperability are still to be solved this approach is not 
mandatory: it is unavoidable!  
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Big multi-institutional medical databases will be technically 
feasible in near future. The validity of such databases 
critically depends on uniform coding and comprehensive 
registration of all clinical relevant information including 
toxicity and long term follow up. Provided all technical 
problems and data protection issues could be solved, the 
question arises what kind of conclusion could be drawn from 
these databases for clinical oncology. Databases will give in 
realistic overview how cancer patients are treated in specific 
situations including the presumably high variability of the 
applied treatments. Clinical outcome data including toxicity 
and survival would give an impression, what can be achieved 
with currently available treatments. The widespread use of 
these databases will likely result in some potentially 
unbeneficial changes in clinical practice and a number of 
risks, if statistical analysis is preformed and causal 
interpretations is pursued. The universal availability of 
clinical outcomes in a big database will led to smaller 
variations of actually applied treatments, since presumably 
favorable treatments would be identified in these databases, 
and physician would prefer to prescribe, what most other 
physician prescribe in the same situation. These presumably 
favorable treatments were likely influenced by a number of 
biases resulting from preconceptions of the oncological 
community. Innovative treatments initiated by single 
investigators or institutes that don’t follow the 
preconceptions of the majority of the oncological community 
maybe hampered, if mainstream treatments derived from big 
databases are easily accessible for home physicians and 
patients. The risk that knowledge form big databases in 
absence of evidence from randomized trials results in self-
fulfilling prophecies is high. One important risk of 
misinterpretation results from the fact that clinical databases 
do typically not allow to perform an intent to treat analysis. 
Since complete documentation of all potentially criteria 
involved in treatment decisions cannot be comprehensively 
documented in a clinical database, the risk of 
misinterpretation is high. Propensity scores have been 
proposes to correct for these biases, but are unable to 
correct for unknown relationships. Whenever causal 
interpretations are derived from big clinical databases, one 
needs to be aware that interpretation requires a high degree 
of caution. Results from clinical big databases should be 
regarded as hypothesis generating and cannot at all be 
considered as substitute for randomized clinical trials. 
Forcing physicians, who have no intrinsic motivation, to 
